FOURLIGHT-1: Atirmociclib Reduces Progression Risk After Prior CDK4/6 Inhibition
oncodaily - Selective CDK4 inhibition has produced its first randomized efficacy signal after progression on conventional CDK4/6 inhibitor therapy in hormone receptor-positive, HER2-negative advanced breast cancer. At ESMO Congress 2026, the randomized […]
AI Summary: FOURLIGHT‑1 reports that atirmociclib meaningfully lowered the risk of progression in patients with endocrine‑resistant metastatic breast cancer previously treated with CDK4/6 inhibitors, extending median progression‑free survival by roughly three months. The results provide a new treatment option for a refractory population, though the clinical impact must be weighed against tolerability and sequencing choices.
Related Stories
Low pCR reported with trastuzumab‑deruxtecan in early breast cancer / 23 hrs
Merck and Moderna report positive phase‑3 melanoma vaccine results / 2 months
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 2 months
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 2 months
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 3 months
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Development, Infant Health, Eli Lilly, Autism and look for the RSS link.
StackHealth Time Machine